FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1981010614> ?p ?o ?g. }

• W1981010614 endingPage "1163" @default.
• W1981010614 startingPage "1154" @default.
• W1981010614 abstract "Sevoflurane (CH2 F-O-CH[CF3]2) reacts with carbon dioxide absorbents to produce Compound A (CH2 F-O-C[=CF2][CF3]). Because of concern about the potential nephrotoxicity of Compound A, the United States package label (but not that of several other countries) for sevoflurane recommends the use of fresh gas flow rates of 2 L/min or more. We previously demonstrated in humans that a 2-L/min flow rate delivery of 1.25 minimum alveolar anesthetic concentration (MAC) sevoflurane for 8 h can injure glomeruli (i.e., produce albuminuria) and proximal tubules (i.e., produce glucosuria and urinary excretion of alpha-glutathione-S-transferase [alpha-GST]). The present report extends this investigation to fasting volunteers given 4 h (n = 9) or 2 h (n = 7) of 1.25 MAC sevoflurane versus desflurane at 2 L/min via a standard circle absorber anesthetic system (all subjects given both anesthetics). Markers of renal injury (urinary creatinine, albumin, glucose, alpha-GST, and blood urea nitrogen) did not reveal significant injury after anesthesia with desflurane. Sevoflurane degradation with a 2-L/min fresh gas inflow rate produced average inspired concentrations of Compound A of 40 +/- 4 ppm (mean +/- SD, 8-h exposure [data from previous study]), 42 +/- 2 ppm (4 h), and 40 +/- 5 ppm (2 h). Relative to desflurane, sevoflurane given for 4 h caused statistically significant transient injury to glomeruli (slightly increased urinary albumin and serum creatinine) and to proximal tubules (increased urinary alpha-GST). Other measures of injury did not differ significantly between anesthetics. Neither anesthetic given for 2 h at 1.25 MAC produced injury. We conclude that 1.25 MAC sevoflurane plus Compound A produces dose-related glomerular and tubular injury with a threshold between 80 and 168 ppm/h of exposure to Compound A. This threshold for renal injury in normal humans approximates that found previously in normal rats. Implications: Human (and rat) kidneys are injured by a reactive compound (Compound A) produced by degradation of the clinical inhaled anesthetic, sevoflurane. Injury increases with increasing duration of exposure to a given concentration of Compound A. The response to Compound A has several implications, as discussed in the article. (Anesth Analg 1997;85:1154-63)" @default.
• W1981010614 created "2016-06-24" @default.
• W1981010614 creator A5006880359 @default.
• W1981010614 creator A5017320268 @default.
• W1981010614 creator A5018442699 @default.
• W1981010614 creator A5026287401 @default.
• W1981010614 creator A5041948994 @default.
• W1981010614 creator A5045833577 @default.
• W1981010614 creator A5047166116 @default.
• W1981010614 date "1997-11-01" @default.
• W1981010614 modified "2023-10-11" @default.
• W1981010614 title "Dose-Related Biochemical Markers of Renal Injury After Sevoflurane Versus Desflurane Anesthesia in Volunteers" @default.
• W1981010614 cites W1893432647 @default.
• W1981010614 cites W1980118488 @default.
• W1981010614 cites W1991289521 @default.
• W1981010614 cites W1994768174 @default.
• W1981010614 cites W1995990906 @default.
• W1981010614 cites W1999988146 @default.
• W1981010614 cites W2000714551 @default.
• W1981010614 cites W2010511402 @default.
• W1981010614 cites W2011690684 @default.
• W1981010614 cites W2019703580 @default.
• W1981010614 cites W2023267822 @default.
• W1981010614 cites W2037766132 @default.
• W1981010614 cites W2037782221 @default.
• W1981010614 cites W2038810811 @default.
• W1981010614 cites W2040281016 @default.
• W1981010614 cites W2064455271 @default.
• W1981010614 cites W2064845525 @default.
• W1981010614 cites W2068139677 @default.
• W1981010614 cites W2074701541 @default.
• W1981010614 cites W2093143336 @default.
• W1981010614 cites W2107524234 @default.
• W1981010614 cites W2123587714 @default.
• W1981010614 cites W2134813600 @default.
• W1981010614 cites W2141584474 @default.
• W1981010614 cites W4238083118 @default.
• W1981010614 cites W4248834402 @default.
• W1981010614 cites W4251608264 @default.
• W1981010614 doi "https://doi.org/10.1097/00000539-199711000-00036" @default.
• W1981010614 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9356118" @default.
• W1981010614 hasPublicationYear "1997" @default.
• W1981010614 type Work @default.
• W1981010614 sameAs 1981010614 @default.
• W1981010614 citedByCount "47" @default.
• W1981010614 countsByYear W19810106142012 @default.
• W1981010614 countsByYear W19810106142014 @default.
• W1981010614 countsByYear W19810106142015 @default.
• W1981010614 countsByYear W19810106142016 @default.
• W1981010614 countsByYear W19810106142017 @default.
• W1981010614 countsByYear W19810106142019 @default.
• W1981010614 countsByYear W19810106142020 @default.
• W1981010614 crossrefType "journal-article" @default.
• W1981010614 hasAuthorship W1981010614A5006880359 @default.
• W1981010614 hasAuthorship W1981010614A5017320268 @default.
• W1981010614 hasAuthorship W1981010614A5018442699 @default.
• W1981010614 hasAuthorship W1981010614A5026287401 @default.
• W1981010614 hasAuthorship W1981010614A5041948994 @default.
• W1981010614 hasAuthorship W1981010614A5045833577 @default.
• W1981010614 hasAuthorship W1981010614A5047166116 @default.
• W1981010614 hasBestOaLocation W19810106141 @default.
• W1981010614 hasConcept C126322002 @default.
• W1981010614 hasConcept C126894567 @default.
• W1981010614 hasConcept C134018914 @default.
• W1981010614 hasConcept C2776125364 @default.
• W1981010614 hasConcept C2776442465 @default.
• W1981010614 hasConcept C2777011798 @default.
• W1981010614 hasConcept C2778162923 @default.
• W1981010614 hasConcept C2778176769 @default.
• W1981010614 hasConcept C2780306776 @default.
• W1981010614 hasConcept C2780472472 @default.
• W1981010614 hasConcept C2781453256 @default.
• W1981010614 hasConcept C42219234 @default.
• W1981010614 hasConcept C71924100 @default.
• W1981010614 hasConceptScore W1981010614C126322002 @default.
• W1981010614 hasConceptScore W1981010614C126894567 @default.
• W1981010614 hasConceptScore W1981010614C134018914 @default.
• W1981010614 hasConceptScore W1981010614C2776125364 @default.
• W1981010614 hasConceptScore W1981010614C2776442465 @default.
• W1981010614 hasConceptScore W1981010614C2777011798 @default.
• W1981010614 hasConceptScore W1981010614C2778162923 @default.
• W1981010614 hasConceptScore W1981010614C2778176769 @default.
• W1981010614 hasConceptScore W1981010614C2780306776 @default.
• W1981010614 hasConceptScore W1981010614C2780472472 @default.
• W1981010614 hasConceptScore W1981010614C2781453256 @default.
• W1981010614 hasConceptScore W1981010614C42219234 @default.
• W1981010614 hasConceptScore W1981010614C71924100 @default.
• W1981010614 hasIssue "5" @default.
• W1981010614 hasLocation W19810106141 @default.
• W1981010614 hasLocation W19810106142 @default.
• W1981010614 hasLocation W19810106143 @default.
• W1981010614 hasOpenAccess W1981010614 @default.
• W1981010614 hasPrimaryLocation W19810106141 @default.
• W1981010614 hasRelatedWork W1991924015 @default.
• W1981010614 hasRelatedWork W2007545336 @default.
• W1981010614 hasRelatedWork W2029221815 @default.
• W1981010614 hasRelatedWork W2053293818 @default.
• W1981010614 hasRelatedWork W2122539177 @default.

• next